Why Brexit Regulation Could Not Function

On 1 August 2023, the Department for Business and Trade announced that the CE mark would be recognised indefinitely across 18 product regulations in Great Britain. Two years earlier, ministers had promised the opposite. The UK was supposed to have its own product mark, its own testing route and its own regulatory footing outside the EU system. The reversal was not just political embarrassment. It was evidence that the state had tried to copy complex regulatory systems without copying the data, staff and testing capacity needed to run them.

The same problem had already surfaced in chemicals. UK REACH, the post-Brexit copy of the EU’s chemicals regime, existed on paper from the moment EU law was carried over into domestic law. The scientific files needed to make that regime work did not come with it. Those files sat in the database of the European Chemicals Agency (ECHA), and the underlying studies were owned by private industry consortia. The law moved. The filing cabinet did not.

The ‘Lift and Shift’ Paradox

UK REACH stands for the UK’s version of the Registration, Evaluation, Authorisation and Restriction of Chemicals regime. It was designed to replace the EU’s REACH system after Brexit while claiming to keep standards high. That was the official premise. The UK would leave the EU’s regulatory structure, keep the legal rules and run its own chemicals system through the Health and Safety Executive, or HSE, the regulator responsible for workplace safety and chemicals oversight.

That sounds tidy until the missing component is named. The EU system did not run on statutory wording alone. It relied on a huge body of safety data built up over years and lodged with ECHA. Those files cover the hazards, uses and exposure risks of thousands of substances. Without access to them, the copied legal regime was incomplete from the start.

That gap mattered because the data was not sitting in a public archive waiting to be transferred. Much of it had been assembled and paid for by industry associations; groups of companies had funded studies together and controlled the rights to use them. The UK government could not simply demand the material from Brussels as if it were lifting boxes from one shelf to another.

The immediate answer from government was to tell UK businesses to submit the information again to HSE. That moved the burden onto the private sector. Firms that had already paid once to support registration in the EU system were now being told they might need to pay again to support registration in the UK system. The duplication was built into the design.

That is where the lift-and-shift error becomes clear. Ministers copied the law, then discovered that the working parts sat elsewhere. The law could be copied into domestic legislation quickly. The evidence base that made it usable could not.

The £2 Billion Ransom

By 2022 and 2023 the cost of fixing that gap had acquired a number. DEFRA and the Chemical Industries Association put the likely cost of obtaining the data rights needed for UK REACH at about £2 billion. That was not the cost of discovering new hazards or filling a scientific blind spot. It was the price of buying back access to information that companies had already funded once for the EU system.

Industry response was hostile for a simple reason. The sector argued that the work would produce no extra safety benefit. The science already existed. The hazard studies had already been carried out. Paying again would not make a chemical better understood. It would only duplicate the paper trail under a second regulator.

That is why industry bodies described the exercise as pointless bureaucracy with an existential price tag. Chemical manufacturing is not a decorative part of the economy. It is a strategic base industry that feeds pharmaceuticals, plastics, agriculture, coatings, detergents and advanced manufacturing. Loading a £2 billion duplication bill onto that sector without a clear safety return was not a minor policy flaw. It raised the question of whether the policy could work at all.

The public documents do not suggest that ministers were trying to lower safety standards. They point to a different failure. The government created a standalone regime before it had a workable way to get hold of the information needed to run it. When that gap became impossible to ignore, the bill was pushed towards industry.

The timetable shifted again and again. Original UK REACH registration deadlines began in October 2021, but they did not last. Later government responses and consultation papers pushed full registration out to October 2029, 2030 and 2031, depending on tonnage and hazard profile. One delay can happen for all sorts of reasons. A string of delays usually points to something deeper.

Each extension also narrowed the room for pretence. Departments still did not have a tolerable way to secure the data. Firms were not willing to pay for duplication at that scale. The regulator was still working without a settled way through the backlog. By then, the timetable was no longer driving events. It was simply logging delay.

The Regulator That Couldn’t Regulate

The National Audit Office laid out the capacity problem. In 2022, they audited the HSE’s Chemicals Regulation Division, the exact unit supposed to take over the EU workload. The auditors found a team trying to expand into a highly technical field while struggling to find enough experienced scientists.

Staff numbers rose sharply. Between 2020 and 2022, the Chemicals Regulation Division increased staffing by 46 per cent. On paper that looks like rapid growth. In practice it came with a heavy training cost. HSE reported that about a quarter of staff time was being absorbed by training new recruits because experienced toxicologists and related specialists were hard to hire.

That is a trap familiar in technical agencies. You can increase headcount and still lose usable capacity. Senior specialists are pulled off live work to train people who are not yet ready to handle the hardest files. Output slows even while payroll rises. The National Audit Office said it would take until at least 2026 for the division to reach full capacity.

The output figures matched that warning. Between 2021 and 2022, the UK initiated only two restriction dossiers. A restriction dossier is the formal package of scientific and legal analysis used to justify limiting or banning risky chemical uses. That number sat far below the EU’s output over the same period. The gap was not rhetorical. It was a measure of what the regulator could actually do.

‘Brain drain’ is a tempting phrase here, but it overstates what the public evidence actually shows. There is no clear sign of a sudden exodus triggered by one ministerial choice. The UK had spent years working inside EU agencies and shared systems, and specialist capacity had grown around that arrangement. When the work had to be done domestically, the gaps showed up in staffing, training and output.

That institutional history turns a political slogan into a staffing ledger. ‘Take back control’ sounds like a constitutional choice. Running a chemicals regime requires trained scientists, assessors and reviewers who can read studies, challenge submissions and write restrictions that stand up. The shortage sat there in the regulator’s workload.

The UKCA Mirage

The same pattern appeared outside chemicals in the attempt to replace the CE mark. The CE mark is the EU’s conformity marking for many goods, used to show that a product meets relevant safety and regulatory requirements. The UK’s replacement was the UKCA mark, short for UK Conformity Assessed. It was meant to become the domestic mark for goods sold in Great Britain after Brexit.

The theory was straightforward. Goods for the British market would move through UK-approved assessment routes and carry a UK mark. The problem was that theory had to meet the physical world of labs, test houses, certification bodies, factory schedules and import chains. That meeting did not go well.

The deadline slipped more than once. The original cut-off was 1 January 2022. That was pushed to 1 January 2023. Then the deadline was pushed again to 31 December 2024. Repeated extension is often presented as pragmatism. Here it also reads as a sign that the infrastructure for enforcement was not ready.

Testing capacity was one reason. The UK did not have enough Approved Bodies across all affected sectors to re-assess the volume of goods previously handled under EU structures. In some areas, that meant delay and extra cost. In others, it raised the risk of empty shelves or blocked supply. Pyrotechnics and construction products were among the sectors where the lack of capacity was especially hard to ignore.

The market logic was brutal. A manufacturer already serving the EU had a route through CE marking for a market of roughly 450 million people. The UK market sits at about 67 million. If the smaller market demands separate testing, separate paperwork and a separate label, some firms will simply stop supplying it.

Industry bodies made the financial reality clear. Make UK warned of a ‘cliff-edge’ if the government forced the switch without the testing and certification base in place. They also pointed to wider trade frictions, including a reported £15 billion annual cost from customs declarations. For manufacturers, the UKCA mark was compounding those costs rather than offering a commercial advantage.

The Indefinite Surrender

The turning point came on 1 August 2023. The Department for Business and Trade announced indefinite recognition of the CE mark for 18 product regulations. The list covered major sectors including toys, radio equipment, personal protective equipment and machinery. Medical devices and construction products remained on separate transitional tracks, but the mandatory UKCA regime for most consumer goods had effectively ended.

That decision left the UKCA mark in an awkward legal half-life. It still existed. Businesses could still use it. For a large share of the market, the economic reason to do so had largely gone. If CE marking remained valid indefinitely in Great Britain, and if many manufacturers already needed CE compliance for EU trade, the incentive to run a second route weakened sharply.

The practical effect was a return to EU-centred product regulation for much of the British market. Goods could keep entering Great Britain under the CE system. If EU standards changed in those sectors, manufacturers serving both markets had every reason to follow the EU route rather than maintain a separate British line. The UK did not formally abolish its own mark. It undercut the case for using it.

The government’s own numbers made the retreat harder to dress up. Its impact assessment for the reversal estimated a net positive of £641 million for UK businesses. That is a large official figure attached to the benefits of abandoning a flagship divergence policy. The saving did not come from a new domestic testing breakthrough. It came from stepping back.

This is the sovereignty problem in ledger form. The state declared that Great Britain would have its own conformity regime. Industry spent time preparing for that shift. Then government concluded that keeping the EU mark in place would save hundreds of millions. The policy survived on paper. The market moved elsewhere.

The Current Stasis, ATRm

By 2024 the chemicals side of the problem had produced a new proposal rather than a clean resolution. DEFRA launched a consultation on an Alternative Transitional Registration model, known as ATRm. The aim was to avoid the full cost of re-obtaining the complete EU-style data package while still giving HSE enough information to regulate.

The compromise was substantial. Consultation material suggested that hazard data requirements for transitional registrations could be reduced by as much as 70 per cent. That is a striking figure because it tells you exactly what had gone wrong. The original copied model was too expensive to operate in a standalone national system, so government started building a lighter version around the cost constraint.

That does not make ATRm meaningless. It may be the only politically and economically workable option left. It does mean the UK is now discussing a chemicals regime that would require less information than the one it had while operating inside the EU structure. The trade-off is visible. Avoid the £2 billion bill, but accept a thinner data base.

The long wait remains. Full registration deadlines now run into the end of the decade and beyond, with staged dates in 2029, 2030 and 2031. That is far removed from the original post-Brexit promise of swift control through a copied domestic regime. The system is still transitional years after the transition.

This is why ‘regulatory limbo’ is not just a rhetorical phrase here. A limbo is a space where the legal rules exist, but the full operating model has not settled. UK REACH is in force. HSE is the domestic regulator. The final information remains unfinished, the deadlines have drifted and the replacement model is still a compromise designed around what cannot be afforded.

The result is a lost decade built into the timetable. The UK has formal independence in chemicals law, but the independent regime still depends on how much data can be cut back without breaking credibility. That is not a clean break from the EU model. It is a prolonged negotiation with the consequences of having left it.

Sources

Sources include: the National Audit Office report ‘Regulating after EU Exit’ (2022); Department for Business and Trade policy announcements and impact assessments regarding CE mark recognition (August 2023); DEFRA consultation documents on the Alternative Transitional Registration model (ATRm); industry cost estimates and lobbying papers from the Chemical Industries Association and Make UK; and statutory guidance on UK Conformity Assessed (UKCA) transitions and deadlines.